Sen. John Boozman Sells Off Shares of Pfizer Inc. (NYSE:PFE)

Senator John Boozman (R-Arkansas) recently sold shares of Pfizer Inc. (NYSE:PFE). In a filing disclosed on March 06th, the Senator disclosed that they had sold between $1,001 and $15,000 in Pfizer stock on February 13th.

Senator John Boozman also recently made the following trade(s):

• Purchased $1,001 – $15,000 in shares of Sprott Lithium Miners ETF (NASDAQ:LITP) on 2/26/2025.
• Purchased $1,001 – $15,000 in shares of Invesco Short Term Treasury ETF (NYSEARCA:TBLL) on 2/26/2025.
• Sold $1,001 – $15,000 in shares of First Trust Global Tactical Commodity Strategy Fund (NASDAQ:FTGC) on 2/26/2025.
• Sold $1,001 – $15,000 in shares of First Trust North American Energy Infrastructure Fund (NYSEARCA:EMLP) on 2/26/2025.
• Purchased $1,001 – $15,000 in shares of Motorola Solutions (NYSE:MSI) on 2/26/2025.
• Purchased $1,001 – $15,000 in shares of Ecolab (NYSE:ECL) on 2/26/2025.
• Purchased $1,001 – $15,000 in shares of Amazon.com (NASDAQ:AMZN) on 2/26/2025.
• Purchased $1,001 – $15,000 in shares of American Express (NYSE:AXP) on 2/26/2025.
• Purchased $1,001 – $15,000 in shares of NVIDIA (NASDAQ:NVDA) on 2/26/2025.
• Sold $1,001 – $15,000 in shares of iShares S&P 500 Growth ETF (NYSEARCA:IVW) on 2/26/2025.

Pfizer Stock Performance

NYSE:PFE opened at $26.71 on Friday. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63. Pfizer Inc. has a 12-month low of $24.48 and a 12-month high of $31.54. The stock has a 50-day moving average price of $26.30 and a 200 day moving average price of $27.24. The stock has a market capitalization of $151.35 billion, a P/E ratio of 18.94, a P/E/G ratio of 0.64 and a beta of 0.61.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, beating the consensus estimate of $0.48 by $0.15. The business had revenue of $17.76 billion during the quarter, compared to analysts’ expectations of $17.26 billion. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The firm’s revenue for the quarter was up 24.7% compared to the same quarter last year. During the same quarter last year, the business posted $0.10 EPS. Equities research analysts forecast that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, March 7th. Investors of record on Friday, January 24th were given a dividend of $0.43 per share. The ex-dividend date was Friday, January 24th. This represents a $1.72 annualized dividend and a dividend yield of 6.44%. This is a boost from Pfizer’s previous quarterly dividend of $0.42. Pfizer’s dividend payout ratio (DPR) is currently 121.99%.

Insider Buying and Selling at Pfizer

In other news, Director Ronald E. Blaylock bought 19,457 shares of the firm’s stock in a transaction on Thursday, February 13th. The stock was acquired at an average cost of $25.65 per share, with a total value of $499,072.05. Following the transaction, the director now directly owns 27,707 shares in the company, valued at approximately $710,684.55. This trade represents a 235.84 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 0.06% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

Several equities analysts have weighed in on PFE shares. Citigroup cut their price target on Pfizer from $30.00 to $29.00 and set a “neutral” rating for the company in a report on Tuesday, January 28th. Wolfe Research started coverage on Pfizer in a report on Friday, November 15th. They set an “underperform” rating and a $25.00 price target for the company. Guggenheim restated a “buy” rating and set a $33.00 price target on shares of Pfizer in a report on Monday, February 10th. UBS Group cut their price target on Pfizer from $31.00 to $29.00 and set a “neutral” rating for the company in a report on Wednesday, January 8th. Finally, Bank of America reiterated a “neutral” rating and issued a $29.00 target price on shares of Pfizer in a report on Tuesday, December 10th. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating, six have assigned a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $31.92.

Institutional Investors Weigh In On Pfizer

A number of institutional investors and hedge funds have recently modified their holdings of PFE. Swedbank AB lifted its stake in shares of Pfizer by 0.7% during the 3rd quarter. Swedbank AB now owns 5,745,831 shares of the biopharmaceutical company’s stock worth $166,284,000 after acquiring an additional 37,636 shares during the last quarter. Moloney Securities Asset Management LLC raised its position in Pfizer by 37.8% during the 3rd quarter. Moloney Securities Asset Management LLC now owns 21,086 shares of the biopharmaceutical company’s stock valued at $610,000 after purchasing an additional 5,785 shares in the last quarter. Cary Street Partners Asset Management LLC raised its position in Pfizer by 7.0% during the 3rd quarter. Cary Street Partners Asset Management LLC now owns 18,865 shares of the biopharmaceutical company’s stock valued at $546,000 after purchasing an additional 1,238 shares in the last quarter. Hanlon Investment Management Inc. bought a new stake in Pfizer during the 3rd quarter valued at $205,000. Finally, NorthRock Partners LLC raised its position in Pfizer by 2.0% during the 3rd quarter. NorthRock Partners LLC now owns 25,102 shares of the biopharmaceutical company’s stock valued at $726,000 after purchasing an additional 497 shares in the last quarter. 68.36% of the stock is owned by institutional investors.

About Senator Boozman

John Boozman (Republican Party) is a member of the U.S. Senate from Arkansas. He assumed office on January 3, 2011. His current term ends on January 3, 2029. Boozman (Republican Party) ran for re-election to the U.S. Senate to represent Arkansas. He won in the general election on November 8, 2022. Boozman won re-election in 2016. He faced Democrat Conner Eldridge, Libertarian Frank Gilbert, and write-in candidate Jason Tate in the general election. Arkansas’ U.S. Senate race was rated as safely Republican in 2016. Boozman began his political career in the U.S. House. He won a special election in 2001 and served in that position until his election to the Senate in 2010. Prior to his political career, Boozman worked as an optometrist. As of a 2014 analysis of multiple outside rankings, Boozman is an average Republican member of Congress, meaning he will vote with the Republican Party on the majority of bills. Below is an abbreviated outline of Boozman’s academic, professional, and political career: 2011-Present: U.S. Senator from Arkansas 2001-2011: U.S. Representative from Arkansas 1977: Graduated from Southern College of Optometry

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.